Molecular Switch Prodrug Activation via HIF-1α Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer therapeutics, particularly gene-directed enzyme prodrug therapy (GDEPT), face challenges in achieving specificity and efficiency due to limitations in gene delivery and viral vector safety, leading to side effects and reduced effectiveness.

Innovation Solution

A novel protein engineering strategy is developed, combining a prodrug activating enzyme with a protein that binds a cancer-specific marker, creating a molecular switch that activates the prodrug only in cancer cells, using a polypeptide comprising cytosine deaminase and a CH1 domain from p300, which is selectively expressed and activated in cells with the cancer marker HIF-1α, converting a prodrug into a toxin.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If gene-directed enzyme prodrug therapy (GDEPT) is used to activate prodrugs in cancer cells, then therapeutic efficacy is improved, but specificity is reduced leading to side effects in normal tissues

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidside effects in normal tissues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines a prodrug-activating enzyme (cytosine deaminase) with a cancer-specific marker-binding domain (HIF-1α binding domain) into a single fusion protein. This merging ensures that the enzyme is only activated in cancer cells that express the HIF-1α marker, thereby improving therapeutic efficacy while reducing side effects in normal tissues through spatial and functional integration of targeting and catalytic activities.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent creates a fusion protein with differentiated functional domains: one domain specifically targets cancer cells by binding to HIF-1α marker, while the other domain contains the prodrug-activating enzyme. This local quality differentiation ensures that prodrug activation occurs only in the specific location (cancer cells) where the marker is present, achieving selective therapy with reduced off-target effects.

Inventive Principle:

Principle #3Local quality

2Productivity

If viral vectors are used for gene delivery in GDEPT, then transduction efficiency is improved, but safety is reduced due to insertional mutagenesis and oncogenesis risks

Engineering Contradiction:

Improvetransduction efficiencyVSAvoidinsertional mutagenesis and oncogenesis

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent uses a fusion protein as an intermediary that delivers the prodrug-activating function to cancer cells without requiring integrative viral vectors. The fusion protein can be delivered via non-integrative methods, acting as a mediator that achieves therapeutic effect without the harmful genomic integration effects of traditional viral vectors, thus maintaining transduction efficiency while eliminating insertional mutagenesis risks.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If transductional targeting is used to deliver genes to cancer cells, then delivery efficiency is improved, but cell specificity is reduced

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidcell specificity

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent incorporates a cancer-specific marker-binding domain (HIF-1α binding domain) into the fusion protein structure in advance. This preliminary action of embedding the targeting function within the therapeutic protein itself ensures that only cancer cells expressing the HIF-1α marker can internalize and activate the prodrug, achieving high cell specificity without compromising delivery efficiency through separate targeting steps.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for targeted and efficient activation of prodrugs in cancer cells, reducing side effects by ensuring that the therapeutic protein is only activated in the presence of the cancer-specific marker, thereby enhancing treatment efficacy while minimizing harm to normal cells.

Implementation Method 1

a protein that binds a cancer specific marker

Methodology Applied

Scientific EffectProtein-protein binding:

Implementation Method 2

the gene encoding an enzyme, which can activate the prodrug

Methodology Applied

Scientific EffectEnzymatic catalysis: Enzyme

Data Source

PatentUS8771679B2Prodrug activation in cancer cells using molecular switches

Publication Date: 2014.07.08 JOHNS HOPKINS UNIVERSITY

AI summary

The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.